FindTrial
Sign In

A medical records based study for the curative effect of combined traditional Chinese and western medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)

Observation of the curative effect of combined traditional Chinese and western medicine in the treatment of severe novel coronavirus pneumonia (COVID-19)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000032040
Enrollment
Unknown
Registered
2020-04-18
Start date
2020-04-01
Completion date
Unknown
Last updated
2020-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Case series:Subcutaneous injection of thymosin a1, take Ma-Xing-Shi-Gan tang and Yin-Qiao powder plus or minus

Sponsors

Affiliated Hospital of Guangdong Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: According to the clinical classification of the fifth edition of the national novel coronavirus pneumonia protocol, COVID 19 patients meet the standard

Exclusion criteria

Exclusion criteria: Patients younger than 18 years of age, older than 75 years of age, pregnant patients, patients with advanced malignancies, patients taking glucocorticoids during severe periods, patients taking other antiretroviral drugs, and those unwilling to sign informed consent

Design outcomes

Primary

MeasureTime frame
28-day mortality;—

Countries

China

Contacts

Public ContactZhang Yuanli

Affiliated Hospital of Guangdong Medical University

zhangyuanly@126.com+86 13828223316

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026